GovChime
Notice ID: 3b3938d3903047c3a5c5d497dc988711JustificationAwarded

Sanofi 20262027 Flu Vaccines

Awarded on September 18, 2026. Full description on SAM.gov.

Overview

Posted
October 21, 2026
Notice type
Justification
NAICS
325412: Pharmaceutical Preparation Manufacturing
Agency
Department of State

Notice details

Office
ACQUISITIONS - AQM MOMENTUM
Place of performance
Swiftwater, Pennsylvania
Last updated
Oct 28, 2026
First published
Last updated on SAM.gov
Award date
Sep 18, 2026
Award amount (SAM.gov award notice)
Not specified

Identifiers

Solicitation number
19AQMM26F1490
Notice ID
3b3938d3903047c3a5c5d497dc988711

Description

Fluzone and Flublok Influenza Vaccines for the 2026-2027 Flu season. The vaccine is required to immunize embassy immunocompromised family members. 

Full description on SAM.gov

Award Overview

Award Number

19AQMM26F1490

Award Amount (SAM.gov award notice)

Not specified

Award Date

Sep 18, 2026

Awardee

Not specified

Original Solicitation

Notice ID: 3b3938d3903047c3a5c5d497dc988711

Posted Date: Oct 21, 2026

Original Response Deadline: Not specified

Other Orders Under Same Vehicle

Top 5 by total obligated

5
  • 75H71124F80034
    SANOFI VACCINES US INC.
    Department of Health and Human ServicesNAICS 325412
    $3.0MSigned Nov 27, 2023
  • 75H71124F80034
    SANOFI VACCINES US INC.
    Department of Health and Human ServicesNAICS 325412
    $3.0MSigned Jan 18, 2024
  • 19AQMM22F4147
    SANOFI VACCINES US INC.
    Department of StateNAICS 325412
    $970.7KSigned Sep 22, 2022
  • 19AQMM24F2196
    SANOFI VACCINES US INC.
    Department of StateNAICS 325412
    $521.5KSigned Sep 17, 2024
  • 36C24623N0652
    SANOFI VACCINES US INC.
    Department of Veterans AffairsNAICS 325412
    $332.1KSigned Apr 13, 2023

More From This Vendor

Top 5 most recent

2
  • 19AQMM23F2166
    SANOFI PASTEUR INC.
    Department of StateNAICS 325412
    $873.8KSigned Jun 17, 2026
  • 19AQMM25F1492
    SANOFI VACCINES US INC.
    Department of StateNAICS 325412
    $176.6KSigned Sep 9, 2025

Contacts

Contracting Officer

Primary Contact

Lesley A. Stewart

Documents

Files (1)

  • Justification and Approval for Other than Full and Open Competition SANOFI 09112026 _Redacted.pdf

    571 KBAdded in Justification version 1Posted
    Download

Lifecycle

  1. 1
    Version 1JustificationCurrent

    Sanofi 20262027 Flu Vaccines

    Notice 3b3938d3903047c3a5c5d497dc988711 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
The Defense Logistics Agency is issuing a solicitation for a national requirements contract for Epinephrine Injectors. Procurement details follow. Epinephrine 0.3 MG/0.3 ML Injection, Auto-Injector 2S in 2 count bottles. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency. A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and Sam.Gov at https://sam.gov. Interested parties should contact Jeremy Brown at (445) 737-5419, (jeremy.brown@dla.mil) for any questions/comments. Interested parties are further advised to set up automated notifications of pre-solicitation or solicitation changes through this website. The current solicitation date is October of 2026.
-Solicitation11/30/2026
The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Fentanyl Citrate Injection Solution. Procurement details follow. Fentanyl (PF) 50 MCG/ML Injection Solution in 1 ML, 2 ML, 5 ML,10 ML, 20 ML and 50 ML in Vials or Ampules, Pack Size of 1, 2, 5, 10, 20, and 50. Competition will be restricted to domestic sources (vendors providing Active Pharmaceutical Ingredients (API) and Final Dosage Forms (FDF) manufactured domestically), the procurement will be competed among all qualified domestic manufacturers. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of War (DoW), Department of Veterans Affairs, Indian Health Service and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency. A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and Sam.Gov at https://sam.gov/. Interested parties should contact Nancy Fernandez at (445) 737-0731 or Nancy.Fernandedz@dla.mil with any questions/comments. Interested parties are further advised to set up automated notifications of pre-solicitation or solicitation changes through this website. The current projected solicitation date is November/December of 2026. DLA reserves the right to issue the solicitation before or after the projected solicitation date.
-Pre-SolicitationOpen
This RFI does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement. Item 0001: OXYGEN, USP, FILLED CYLINDER, SIZE D, 95GAL, TYPE I-DOT 3AA STEEL NSN: 6505-00-132-5181 Shall be made in accordance with MIL-O-37997 DATED 18 DECEMBER 1985 (attached) and changes listed in the attachment to this notice. Item 0002: OXYGEN, USP, FILLED CYLINDER, SIZE H, 1650 GAL, TYPE I-DOT 3AA STEEL NSN: 6505-00-132-5199 Shall be made in accordance with MIL-O-37997 DATED 18 DECEMBER 1985 (attached) and changes listed in the attachment to this notice. Item 0003: NITROUS OXIDE, USP, FILLED CYLINDER, SIZE D, 250 GAL, TYPE I-DOT 3AA STEEL NSN: 6505-00-130-1920 Shall be made in accordance with MIL-N-37996 DATED 24 DECEMBER 1985 (attached) and changes listed in the attachment to this notice. ----------------------------------------------------- The Defense Logistics Agency Troop Support is seeking sources capable of providing the Medical Gas Cylinder in accordance with the Military Specifications listed above. NOTE: Only Type I-DOT 3AA STEEL Medical Gas Cylinders are acceptable. If your firm currently manufactures or distributes Type I-DOT 3AA STEEL Medical Gas Cylinders in accordance with the Military Specifications and changes attached, please provide information with respect to the following: Source and Part Number being supplied for each type of cylinder Place of manufacture for each type of cylinder Source for the Medical Gases Current unit sale price for each type of cylinder prefilled with the medical grade gas Estimated annual capacity for each type of cylinder/medical grade gas Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for the ATNAA. All information submitted shall remain with the U.S. Government and will not be returned. It will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002. Your response to this RFI may be submitted electronically via emailed to Jessica De La Hoz, Contracting Officer, Phone: 445-737-3623, Email: Jessica.DeLaHoz@dla.mil
-Market Research11/15/2026
-AwardedOpen
INTENT TO SOLE SOURCE The Department of Veterans Affairs, Network Contracting Office 4 (NCO4) intends to sole source a contract for Lutathera & Pluvicto for the Lebanon VA Medical Center. All work is to be completed in accordance with statement of work. This sole source contract will be solicited and negotiated with Novartis Pharmaceuticals Corporation, 59 Route 10, East Hanover, NJ 07936-1080 under the deviation outlined in the Revolutionary FAR Overhaul (RFO) for FAR 8.4 - Ordering under the Federal Supply Schedule and GSAM/R 538.71, as required by Executive Order (E.O.) 14275, Restoring Common Sense to Federal Procurement, signed April 15, 2025. Deviation effective date: November 3, 2025. See attached Draft Statement of Work (SOW). The North American Industry Classification System (NAICS) code for this procurement is 325412. The Small Business Administration (SBA) size standard is 1300 employees. Interested vendors that can meet this requirement, shall identify their interest and capability, and respond to this notice by 11/03/2026 by 1400 pm EST. Interested vendors must send a capability statement, no more than one page in length; to include Company Name, SAM UEI Number, Socioeconomic Category, brief description of your business entities capability to handle this project at the Lebanon VA Medical Center. This Special Notice of Intent to Sole Source is for planning purposes only. No solicitation will be made available. This is not a request for quotations. All information shall be provided at no cost or obligation to the Government. Responses must be sent via email to the Contracting Specialist at cynthia.laemmerhirt@va.gov. Responses received will be evaluated; however, a determination by the Government not to compete the proposed procurement based upon the responses to this notice is solely at the discretion of the Government. If no responses are received, Contracting will proceed with the sole source negotiation with Norvartis Pharmaceuticals Corporation.
-Special Notice11/03/2026

Additional Details

Solicitation Number

19AQMM26F1490

Archive Date

Nov 20, 2026

Office Address

WASHINGTON, DC, 20520